+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Primary Immune Deficiency (PID) - Pipeline Insight, 2024 - Product Thumbnail Image

Primary Immune Deficiency (PID) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
From
Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • December 2024
  • 240 Pages
  • Global
From
Neurodegenerative Disorder Therapeutics Global Market Report 2024 - Product Thumbnail Image

Neurodegenerative Disorder Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Tumor Necrosis Factor Inhibitor Drugs Market Report 2025 - Product Thumbnail Image

Tumor Necrosis Factor Inhibitor Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Anti-Parkinson Drugs Global Market Report 2024 - Product Thumbnail Image

Anti-Parkinson Drugs Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
Myasthenia Gravis - Pipeline Insight, 2024 - Product Thumbnail Image

Myasthenia Gravis - Pipeline Insight, 2024

  • Clinical Trials
  • June 2024
  • 80 Pages
  • Global
From
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets - Product Thumbnail Image

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

  • Report
  • December 2024
  • 125 Pages
  • Global
From
Loading Indicator